BRIEF published on 01/20/2025 at 18:05, 1 year 4 months ago Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Transparency Notification Share Acquisition Atlas Special Opportunities Oxurion Retinal Disease Therapies
BRIEF published on 01/20/2025 at 18:05, 1 year 4 months ago Oxurion reçoit une notification de transparence de la part d'Atlas Special Opportunities LLC Acquisition D'actions Oxurion Opportunités Spéciales Atlas Avis De Transparence Thérapies Pour Les Maladies De La Rétine
PRESS RELEASE published on 01/20/2025 at 18:00, 1 year 4 months ago Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion NV receives transparency notification regarding shares ownership from Atlas Special Opportunities, LLC, crossing the 20% threshold. Company engaged in developing ophthalmic therapies Transparency Notification Ophthalmic Therapies Oxurion NV Shares Ownership Belgian Transparency Legislation
PRESS RELEASE published on 01/20/2025 at 18:00, 1 year 4 months ago Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities LLC Oxurion NV ontvangt transparantiekennisgeving van Atlas Special Opportunities LLC over aankoop aandelen, voldoet aan Belgische transparantiewetgeving. Oogheelkundig bedrijf gevestigd in Leuven, België Transparantiekennisgeving Oxurion NV Biofarmaceutisch Netvliesaandoeningen Belgische Transparantiewetgeving
BRIEF published on 01/14/2025 at 18:05, 1 year 5 months ago Oxurion reçoit une mise à jour de transparence d'Atlas Special Opportunities LLC Actions Atlas Transparence Biopharmaceutique Oxurion
BRIEF published on 01/14/2025 at 18:05, 1 year 5 months ago Oxurion Receives Transparency Update from Atlas Special Opportunities LLC Actions Transparency Atlas Biopharmaceutical Oxurion
PRESS RELEASE published on 01/14/2025 at 18:00, 1 year 5 months ago Oxurion ontvangt aangepaste transparantiekennisgeving van Atlas Special Opportunities LLC Oxurion NV ontvangt aangepaste transparantiekennisgeving van Atlas Special Opportunities LLC wegens verkoop van aandelen. Leuven biofarmaceutisch bedrijf actief in oftalmologische therapieën Transparantiekennisgeving Oxurion NV Biofarmaceutisch Oftalmologische Therapieën België
PRESS RELEASE published on 01/14/2025 at 18:00, 1 year 5 months ago Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities LLC Oxurion NV announces receiving an amended transparency notification regarding share ownership by Atlas Special Opportunities, LLC, crossing under the 3% threshold Transparency Notification Share Ownership Atlas Special Opportunities LLC Oxurion NV Retinal Disease
BRIEF published on 01/13/2025 at 18:05, 1 year 5 months ago Oxurion Updates Voting Rights Following Convertible Bond Conversion Voting Rights Convertible Bonds Capital Increase Market Opportunities Oxurion
BRIEF published on 01/13/2025 at 18:05, 1 year 5 months ago Oxurion met à jour ses droits de vote suite à la conversion des obligations convertibles Obligations Convertibles Augmentation De Capital Droit De Vote Opportunités De Marché Oxurion
Published on 06/20/2026 at 01:00, 9 hours 44 minutes ago Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 10 hours 44 minutes ago Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 1 day 6 hours ago Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 1 day 9 hours ago American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 1 day 9 hours ago Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting
Published on 06/20/2026 at 06:00, 4 hours 44 minutes ago Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 14 hours 27 minutes ago 2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 20:17, 14 hours 27 minutes ago 2CRSi SA: 2CRSi répond point par point au rapport de Grizzly Research et réaffirme la réalité de son activité
Published on 06/19/2026 at 19:01, 15 hours 43 minutes ago Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting
Published on 06/19/2026 at 19:33, 15 hours 11 minutes ago Déclaration hebdomadaire d'opérations effectuées du 15 au 19 juin 2026
Published on 06/19/2026 at 19:33, 15 hours 11 minutes ago Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 15 hours 21 minutes ago Imerys-06-2026-communique-capital-droits-de-vote-au-31-mai-2026
Published on 06/19/2026 at 19:23, 15 hours 21 minutes ago Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
